The following could bode well for our CDH17 drug given that Neuroendocrine Tumors is one of our targets!
https://endpts.com/aadi-axes-80-of-staffers-as-it-winds-down-phase-2-solid-tumor-trial-thats-unlikely-to-succeed/
Eventhough trial enrolment is being paused, the 10 NET patients who have been recruited and dosed will continue to receive treatment. Their initial efficacy analysis should be available at the end of the year. Worth keeping an eye on.
Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.76K | 2.928M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4817793 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18563373 | 21 |
View Market Depth
| Last trade - 14.13pm 26/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |